Basket | Login | Register

 
 
 
 

Amoneta Diagnostics describes its biobank of biological samples from patients with dementia and cognitively intact subjects

Tuesday 20 November 2018

Amoneta Diagnostics is a life sciences biotechnology company that identifies, develops and qualifies innovative biomarkers for the development of diagnostics and diagnostic tools in the field of neurological diseases.  The Amoneta Diagnostics team is coordinating both the ADKIT (EuroTransBio; GA # 931/14/C1) and the ADDIA (H2020; GA # 674474, ClinicalTrials.gov Identifier: NCT03030586) projects. Thanks to these two European programs, Amoneta diagnostics has developed a biobank of biological samples from patients with Alzheimer’s disease (AD). The biobank is certified NFS96 900:  ID 112741164528.

The AD biobank has been officially launched during the ADDIA annual meeting in Strasbourg (France) in July 2018. The sample collection has started in March 2016 for the ADKIT study and in January 2017 for the ADDIA study. The liquid biopsies have been collected from patients with AD and other neurodegenerative diseases, including dementia with Lewy body, frontotemporal dementia, corticobasal degeneration and progressive supranuclear palsy, and from healthy controls.

This biobank comprises high-quality and anonymised biological material and its associated information:

  • The biological material consists in following liquid biopsies: whole blood, plasma, serum, peripheral blood mononuclear cells (PBMCs), blood RNA and DNA, cerebrospinal fluid (CSF), urine and saliva samples.
  • The afferent information includes demographic, clinical, neurocognitive scores and neuroimaging data (volumetric 3D MRI), CSF Aβ1-42 and CSF tau data, and blood biochemistry and haematology results.

Together with Amoneta Diagnostics, several organisations have been involved in the development of the AD biobank including Besançon CHU, Brescia IRCCS, Brussels Cliniques Universitaires Saint-Luc, Brussels Erasme Hospital, Colmar Hospital, Firalis SA, Geneva University Hospital, Istanbul faculty of Medicine, Lausanne CHUV, Lille CHU, Montpellier CHU, Nice CHU, Paris AP-HP, Strasbourg University Hospital; with the support of Alzheimer Europe. The company is pleased to share its AD biobank for research purposes. The biobank gives the opportunity to a large number of research investigators to collaborate on the use of the biological samples. For further information please visit the ADDIA website or contact: biobank@firalis.com  

Options